Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | FASN | P49327 | 1/20 | 0.38 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KAT2A | Q92830 | 2/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | PRKCA | P17252 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4304636 | 0.88 | KAT2A (0.41) | POLBFASNKAT2A | |
| SCHEMBL4304676 | 0.79 | — | — | |
| SCHEMBL2949970 | 0.76 | POLB (0.36) | POLBFASNDAGLACYP1A2KDM4E | |
| SCHEMBL23528827 | 0.73 | POLB (0.33) | POLBFASNDAGLACYP1A2KDM4E | |
| SCHEMBL17589655 | 0.72 | POLB (0.41) | POLBFASNDAGLACYP1A2PRKCA | |
| SCHEMBL8935521 | 0.71 | KAT2A (0.42) | POLBFASNDAGLACYP1A2KAT2A | |
| SCHEMBL7689986 | 0.71 | — | — | |
| SCHEMBL7699936 | 0.71 | PRKCA (0.50) | POLBFASNDAGLACYP1A2PRKCA | |
| SCHEMBL2953958 | 0.71 | POLB (0.41) | POLBFASNDAGLACYP1A2PRKCA | |
| SCHEMBL2949950 | 0.69 | POLB (0.43) | POLBFASNDAGLACYP1A2PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114615999-B | Drug antibody conjugates | 法马马有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-114615999-A | Drug antibody conjugates | 法马马有限公司 | 2022-06-10 | — | — | CN | disclosed |
| EP-1919290-A2 | METHODS AND PRODUCTS FOR TREATMENT OF DISEASES | DMI Biosciences, Inc. (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007009087-A2 | METHODS AND PRODUCTS FOR TREATMENT OF DISEASES | DMI BIOSCIENCES, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| CN-1798576-A | Drug for preventing or treating angiogenic eye diseases | SANKYO CO (JP) | 2006-07-05 | — | — | CN | disclosed |
| EP-1336407-B1 | COMPOSITION CONTAINING AN ANGIOTENSIN II RECEPTOR ANTAGONIST AND A DIURETIC AND ITS USE FOR THE TREATMENT OF HYPERTENSION | SANKYO CO (JP) | 2006-05-03 | — | — | EP | disclosed |
| CN-1165533-C | Spiropiperidine derivatives | ������������ʽ���� | 2004-09-08 | — | — | CN | disclosed |
| EP-1377577-A1 | PYRROLE DERIVATES FOR TREATING CYTOKINE MEDIATED DISEASES | Sankyo Company Limited (JP) | 2004-01-07 | — | — | EP | disclosed |
| WO-2003106435-A1 | FUSED-RING PYRIMIDIN-4(3H)-ONE DERIVATIVES, PROCESSES FOR THE PREPARATION AND USES THEREOF | SANKYO COMPANY, LIMITED (JP) | 2003-12-24 | — | — | WO | disclosed |
| EP-1336407-A1 | MEDICINAL COMPOSITIONS | Sankyo Company, Limited (JP) | 2003-08-20 | — | — | EP | disclosed |
| WO-2003066633-A1 | NOVEL PYRANOSYL CYTOSINES: PHARMACEUTICAL FORMULATIONS AND METHODS | ISIS PHARMACEUTICALS, INC. (US) | 2003-08-14 | — | — | WO | disclosed |
| WO-2002057264-A1 | PYRROLE DERIVATES FOR TREATING CYTOKINE MEDIATED DISEASES | SANKYO COMPANY LIMITED (JP) | 2002-07-25 | — | — | WO | disclosed |
| CN-1304402-A | Sulfonamide derivatives | SANKYO CO (JP) | 2001-07-18 | — | — | CN | disclosed |
| CN-1294588-A | Spiropiperidine derivatives | SANKYO CO (JP) | 2001-05-09 | — | — | CN | disclosed |
| WO-2001002413-A1 | BAFIlOMYCIN DERIVATIVES WITH ANTICANCER ACTIVITY | INSTITUTO BIOMAR S.A. (ES) | 2001-01-11 | — | — | WO | disclosed |
| EP-0763053-A4 | STEROID DERIVATIVES FOR TREATMENT OF 5 ALPHA REDUCTASE | SMITHKLINE BEECHAM CORP (US) | 1998-09-09 | — | — | EP | disclosed |
| EP-0763053-A1 | STEROID DERIVATIVES FOR TREATMENT OF 5 ALPHA REDUCTASE | SMITHKLINE BEECHAM CORPORATION (US) | 1997-03-19 | — | — | EP | disclosed |
| WO-1995033761-A1 | STEROID DERIVATIVES FOR TREATMENT OF 5 ALPHA REDUCTASE | SMITHKLINE BEECHAM CORPORATION (US) | 1995-12-14 | — | — | WO | disclosed |